Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- Nature IndexSCIEScopus
- 저널 순위
- JCR Q1
- 저널
- NATURE477(7362) · pp.99 · 2011
- 피인용
- Web of Science 471
- JCR IF
- JCR 2010 36.104
- ISSN
- 0028-0836
저자
- Breitbach, Caroline J.제1저자Jennerex Inc., United States
- Burke, JamesJennerex Inc., United States
- Jonker, DerekOttawa Hospital Research Institute, Canada
- Stephenson, JoeCancer Centers of the Carolinas, United States
- Haas, Andrew R.University of Pennsylvania Medical Center, United States
- Chow, Laura Q. M.Ottawa Hospital Research Institute, Canada
- Nieva, JorgeDepartment of Hematology/Oncology, Billings Clinic, United States
- 황태호Pusan National University, South Korea
- Moon, AnneJennerex Inc., United States
- Patt, RichardRadMD, United States
- Pelusio, AdinaJennerex Inc., United States
- Le Boeuf, FabriceOttawa Hospital Research Institute, Canada
- Burns, JoeOttawa Hospital Research Institute, Canada
- Evgin, LauraOttawa Hospital Research Institute, Canada
- De Silva, NaomiOttawa Hospital Research Institute, Canada
- Cvancic, SaraOttawa Hospital Research Institute, Canada
- Robertson, TerriJennerex Inc., United States
- Je, Ji-EunPusan National University, South Korea
- 이연숙Pusan National University, South Korea
- Parato, KelleyOttawa Hospital Research Institute, Canada
- Diallo, Jean-SimonOttawa Hospital Research Institute, Canada
- Fenster, AaronRobarts Research Institute, Canada
- Daneshmand, ManijehOttawa Hospital Research Institute, Canada
- Bell, John C.Ottawa Hospital Research Institute, Canada
- Kirn, David H.교신저자Jennerex Inc., United States
초록
The efficacy and safety of biological molecules in cancer therapy, such as peptides and small interfering RNAs (siRNAs), could be markedly increased if high concentrations could be achieved and amplified selectively in tumour tissues versus normal tissues after intravenous administration. This has not been achievable so far in humans. We hypothesized that a poxvirus, which evolved for blood-borne systemic spread in mammals, could be engineered for cancer-selective replication and used as a vehicle for the intravenous delivery and expression of transgenes in tumours. JX-594 is an oncolytic poxvirus engineered for replication, transgene expression and amplification in cancer cells harbouring activation of the epidermal growth factor receptor (EGFR)/Ras pathway, followed by cell lysis and anticancer immunity(1). Here we show in a clinical trial that JX-594 selectively infects, replicates and expresses transgene products in cancer tissue after intravenous infusion, in a dose-related fashion. Normal tissues were not affected clinically. This platform technology opens up the possibility of multifunctional products that selectively express high concentrations of several complementary therapeutic and imaging molecules in metastatic solid tumours in humans.
키워드
VACCINIA VIRUSGM-CSFIMATINIB MESYLATETHYMIDINE KINASEMEASLES-VIRUSGROWTH-FACTORTHERAPYTUMORSCRITERIAPROGRESS
식별자
- WoS UID
- 000294404300039



로그인
연구물 목록으로